Serum CXCL10 and CRP Levels in Patients with Acne Vulgaris in Correlation with Disease Severity

NCT ID: NCT06869109

Last Updated: 2025-03-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

88 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-10

Study Completion Date

2026-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the correlations between CXCL10 levels, CRP, and acne severity scores (e.g., Global Acne Grading System) suggest that CXCL10 could serve as a biomarker of inflammation and acne severity. Understanding the relationship between CXCL10, CRP, and acne severity may offer insights into novel therapeutic strategies targeting inflammatory pathways in acne.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cross-sectional Observational Study. using 4 groups a 3 of different acne severity and controle one . the serum cxcl10 and crp will measured in each patient to correlate with disease severity

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mild acne group

mild disease severity

serum cxcl10

Intervention Type DIAGNOSTIC_TEST

serum blood sample to measure the cxcl10

serum crp

Intervention Type DIAGNOSTIC_TEST

blood sample to measure crp

moderate acne group

moderate disease severity

serum cxcl10

Intervention Type DIAGNOSTIC_TEST

serum blood sample to measure the cxcl10

serum crp

Intervention Type DIAGNOSTIC_TEST

blood sample to measure crp

severe acne group

severe disease severity

serum cxcl10

Intervention Type DIAGNOSTIC_TEST

serum blood sample to measure the cxcl10

serum crp

Intervention Type DIAGNOSTIC_TEST

blood sample to measure crp

control group

healthy people

serum cxcl10

Intervention Type DIAGNOSTIC_TEST

serum blood sample to measure the cxcl10

serum crp

Intervention Type DIAGNOSTIC_TEST

blood sample to measure crp

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum cxcl10

serum blood sample to measure the cxcl10

Intervention Type DIAGNOSTIC_TEST

serum crp

blood sample to measure crp

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged 12-40 years diagnosed with acne vulgaris.
2. Both genders included.
3. Patients with mild, moderate, or severe acne severity as determined by a validated scoring system (e.g., Global Acne Grading System).
4. Patients not on systemic acne treatment (e.g., isotretinoin or antibiotics) or anti-inflammatory drugs.

Exclusion Criteria

1. Patients with autoimmune diseases, systemic illnesses, acute infection or any other chronic inflammatory conditions that may affect CRP or CXCL10 levels.
2. Pregnant or lactating individuals.
Minimum Eligible Age

12 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dina Essam

physician assiut university student hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Doaa Samir, prof

Role: STUDY_DIRECTOR

Assiut University

Ahmed Shawky, prof

Role: STUDY_DIRECTOR

Assiut University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assiut University

Asyut, Asyut Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dina Essam, physician

Role: CONTACT

+201027664829

References

Explore related publications, articles, or registry entries linked to this study.

Abdelrazik YT, Ali FM, Salek MS, Finlay AY. Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI). Br J Dermatol. 2021 Oct;185(4):711-724. doi: 10.1111/bjd.20391. Epub 2021 Jul 22.

Reference Type BACKGROUND
PMID: 33864247 (View on PubMed)

Alsulaimani H, Kokandi A, Khawandanh S, Hamad R. Severity of Acne Vulgaris: Comparison of Two Assessment Methods. Clin Cosmet Investig Dermatol. 2020 Sep 28;13:711-716. doi: 10.2147/CCID.S266320. eCollection 2020.

Reference Type BACKGROUND
PMID: 33061511 (View on PubMed)

Stańkowska A, Bergler-Czop B, Brzezińska-Wcisło L. Interleukins-6, -8 and -12p40 and C-reactive protein levels in patients with acne vulgaris with various severityof skin changes. Dermatology Review/Przegląd Dermatologiczny. 2020;107(4):308-22

Reference Type BACKGROUND

Yang CC, Huang YT, Yu CH, Wu MC, Hsu CC, Chen W. Inflammatory facial acne during uncomplicated pregnancy and post-partum in adult women: a preliminary hospital-based prospective observational study of 35 cases from Taiwan. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1787-1789. doi: 10.1111/jdv.13667. Epub 2016 Apr 22.

Reference Type BACKGROUND
PMID: 27102946 (View on PubMed)

Kutlu O, Karadag AS, Unal E, Kelekci KH, Yalcinkaya Iyidal A, Topaloglu Demir F, Aksoy B, Colgecen E, Tosun M, Emre S, Tatliparmak A, Demirseren DD, Kaya Ozden H, Ozturk M, Ozlu E, Chen W. Acne in pregnancy: A prospective multicenter, cross-sectional study of 295 patients in Turkey. Int J Dermatol. 2020 Sep;59(9):1098-1105. doi: 10.1111/ijd.14999. Epub 2020 Jun 20.

Reference Type BACKGROUND
PMID: 32562263 (View on PubMed)

Ansar W, Ghosh S, Ansar W, Ghosh S. Inflammation and inflammatory diseases, markers, and mediators: role of CRP in some inflammatory diseases. Biology of C reactive protein in health and disease. 2016:67-107

Reference Type BACKGROUND

Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86. doi: 10.1002/hep.1840120517.

Reference Type BACKGROUND
PMID: 1699862 (View on PubMed)

Yu H, Zhang B, Zhan Y, Yi Y, Jiang Q, Zhang Q, Wu Y, Wu M. Neutrophil extracellular trap-related mechanisms in acne vulgaris inspire a novel treatment strategy with adipose-derived stem cells. Sci Rep. 2024 Jan 17;14(1):1521. doi: 10.1038/s41598-024-51931-w.

Reference Type BACKGROUND
PMID: 38233540 (View on PubMed)

Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis. 2010 Dec 9;9:141. doi: 10.1186/1476-511X-9-141.

Reference Type BACKGROUND
PMID: 21143923 (View on PubMed)

Jin Z, Song Y, He L. A review of skin immune processes in acne. Front Immunol. 2023 Dec 15;14:1324930. doi: 10.3389/fimmu.2023.1324930. eCollection 2023.

Reference Type BACKGROUND
PMID: 38193084 (View on PubMed)

Liang J, Chen Y, Wang Z, Wang Y, Mu S, Zhang D, Wang Z, Zeng W. Exploring the association between rosacea and acne by integrated bioinformatics analysis. Sci Rep. 2024 Feb 6;14(1):3065. doi: 10.1038/s41598-024-53453-x.

Reference Type BACKGROUND
PMID: 38321132 (View on PubMed)

Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29.

Reference Type BACKGROUND
PMID: 21880356 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

role of CXCL10 and CRP in acne

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Serum TWEAK Levels in Acne Vulgaris
NCT05684861 COMPLETED PHASE2